Biotech Values

[urche]

CRME (cryo, cyt.to)

From what i hear in my neck of the woods, this drug isn't going to get much usage.

Interesting you should say that, PGS, because that would be my own gut feeling as well.The market's reaction corroborates your sentiment, too.

The drug, being intravenous, would only be attractive in the minority of acute atrial fib patients for whom simple rate control and anticoagulation or urgent electrical cardioversion were not preferred options. Even then, something like 50% of acute a fib pt's convert spontaneously within a day or so and a good hunk of the rest would face a serious cost-effectiveness analysis about whether to use this Cardiome drug.

I wouldn't go so far as to short CRME, but I am very interested in the cryoablation companies, Cryocath and Cryocor. That seems a very attractive technology, though I can't make up my mind whether there is an investment opportunity there.

Urche